後醫系二年級 張育瑋
•Introduction
研習學生: 101000008 後醫二 張育瑋
研習地點: Department of Biochemistry, Duke University
Medical Center,
USA
指導老師: Dr. Vann Bennett
Professor
指導老師: Dr. Vann Bennett
Professor
Department of Biochemistry, Duke
University
Medical Center, USA
研究題目: Stability of AnkyrinG by Beta-II Spectrin in
研究題目: Stability of AnkyrinG by Beta-II Spectrin in
Mammalian Epithelial Cell
•Outline
1. Picture in Duke University and Dr. Bennett’s lab
2. Lab Meeting Presentation I
3. Lab Meeting Presentation II
4. Journal Club Presentation
2. Lab Meeting Presentation I
3. Lab Meeting Presentation II
4. Journal Club Presentation
•Pictures: Duke University
•Pictures: Vann’s Lab
•Lab Meeting
•
•
•2013.8.27 Yu-Wei
•
•AnkG Level
•AnkG Level
•Beta II Spectrin Level
•Beta II - Spectrin Level
•Lab Meeting
•
•
•2013.9.4 Yu-Wei
•
•AnkG Level
•AnkG Level
•Beta II Spectrin Level
•Beta II - Spectrin Level
•B2 Expression Level
•B2 Expression Level
•Journal Club
•Bispecific antibodies directed to CD4
domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1
•
Pace CS, Song R, Ochsenbauer C, Andrews CD, Franco D, Yu J, Oren DA, Seaman MS, Ho DD.
Pace CS, Song R, Ochsenbauer C, Andrews CD, Franco D, Yu J, Oren DA, Seaman MS, Ho DD.
•
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13540-5.
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13540-5.
•
• Presented
by Yu-Wei Chang
•2013.8.23
•Bispecific
Antibodies directed to CD4 Domain 2 and HIV Envelope
1. PG9, PG16
a. anti-gp120
b. neutralize ∼80% of HIV-1 strains
a. anti-gp120
b. neutralize ∼80% of HIV-1 strains
2. iMab
a. humanized anti-CD4 Ab ibalizumab
b. established safety record and anti–HIV-1 activity in
clinical trials
•Schematic
Structure of PG9-iMab
•Stability
and Thermaostability
•Neutralization
breadth and potency
of PG9-iMab and PG16-iMab
of PG9-iMab and PG16-iMab
•IC50 of
PG9-iMab and PG16-iMab
•Viral
Coverage of PG9-iMab and PG16-iMab
•The
mechanism behind the exceptional
breadth and potency of BibNAbs
breadth and potency of BibNAbs
1.Merely to the synergism
●
2.bivalent binding PG9/ PG16
to two gp120 molecules
●
3. anchor the active anti-Env site on cell surface CD4
•PG9-ΔiMab
•Combination
in different ratio of iMab to PG9
•PG9-PRO
140
•PG9-iMAb
VS iMab-PG9
•Linker
Length
•
•Modeling
•Prospective
1. Pharmacokinetics
2. Manufacturability
3. Immunogenicity
2. Manufacturability
3. Immunogenicity
•
留言